Member Info for notaflipper

Great find. Aside from highlighting the obvious problem of having a company's name starting with "Y" it does show out of the 294 companies that circa 236 have emergency use authorization (EUA) for the US an that 99 of these have CE accreditation (and 61 of these are PCR based). The low 19 Asian accreditation perhaps might that they are deferring to the CE and WHO Emergency Use accreditation but is noticeable.

The limitations of this table though is that it doesn't have a column on test accuracy, number of genes tested and whether the test is antigen or an antibody test. With those filters added there are less comparables. Interestingly whereas Novacyt / Primerdesign is shown those invested in ODX, AVCT will notice they are missing. As a PCR test new novel technology from Avacta and GDR has captured the market's attention more. I have been amazed at how their sp and market valuations have changed despite that there may being some reservations as reflected by the Covid-19 National Diagnostic Research and Evaluation platform (CONDOR). It will be interesting to see just how these new technologies will fare by the end of all of this.

I wrote to 'investors@ipfin.co.uk' to confirm thee Tweet statement as it goes against the media comms of last two months and is admittedly a strange thing to confirm via RNS. Was hoping this could be a mix-up by their social content blogger. However have not heard a response yet. Strange tick-up in the afternoon which could be that others still not in the know or some other news expected. Agree with the sentiments that this needs to start moving and the trading pattern over last two months is starting to get a bit tedious.

Apparently this is the thread
https://twitter.com/IPFplc/status/1281515878065086465

Confused whether they are referring to the August update being rolled into September and not the July update being rolled into September update. Seems a bit surprising given their communication strategy to this point.

Thanks. You made me smile :-)

Trading update is coming out on Monday which will give update on debt repayments, collections and credit issued. Given the fair wind behind following from the last trading update for June the figures should do better. To be honest I think there's a bit of manipulation going on with the usual drop in the mornings to only see the sp rise in the afternoon. If you look at the trading performance the day before the last trading update was issued similar games were played with a drop only to spike following the update release. Seems like more of the same and lets hope some PIs know the game.

JAdam I think the last day has made clear that it was not PIs nor BB sentiment that has lead to the trading pattern in the last few months. But that being that the placing has been known about for a while by those IIs involved and the sp manipulated accordingly to the detriment of shareholders this last few months. I would advise that the holdings of an individual PI and their views cannot influence of share of over 600m shares so lets not inflate any PIs ego for no reason.
Thanks and much appreciated.

Rising quickly over 60p in the back. Think trading update will show more bonds due in 2021 will have been repaid and that Group collections effectiveness goes over 90% of pre-Covid expectations.

Yep. Placing has been known for ages methinks too. Hence the suppressed sp and what will inevitably be a very quick Bookbuild. Can look at it another way "the handcuffs are off!"...now where did I hear that before?

If correct though you should see the sp appreciate regardless of any PIs banking profits along the way. Although commitments are only $5m in short-term to a potential of $11m by FY22 they're raising potentially $13.5m. So expecting another acquisition in the short-term (pre-Half Year trading update) in addition to announcements of massive capital expenditure.

As the Good Doctor would say "Now wash your hands".

Premaitha Health (former name of YourGene) signed a partnership agreement of Coastal Genomics on the 11th June 2018 hence why the name maybe familiar to some LTHs. The partnerships was to develop advanced technologies for clinical DNA sequencing tests ~ basically to optimise DNA sampling.

We will probably hear that the Placing was oversubscribed though the IR approach has been baffling for many months. My understanding is that the commitments to Coastal Genomics are £11m but the placing will raise £13m. So a headroom of a further £2m for further acquisitions.

With Coastal Genomics having sales targets of US$4.0m for the 2022FY and US$8.5m in FY23, this surely now would have to be added to Yourgene Health targets and a revised broker rating must be forthcoming shortly and cannot await till the Quarterly update. Obviously this is difficult to track down for a YGEN investor but I seem to recall Sales targets was circa £28m for FY22 and discounted for any IONA Nx, Clarigene COVID-19 test and any DPYD sales.

The mention in the RNS of NIPT I think is a reference that NIPT is available to all pregnant individuals in Ontario, and is covered by Ontario Health Insurance Plan (OHIP) etc. Hence the RNS suggesting this will drive NIPT sales growth.

The revenues is £0.6m and net assets of £0.8m but the initial acquisition amount is staged as below:

cash consideration on Completion of US$3.0m;
consideration of US$2.5m payable by the issuance on Completion of Initial Consideration Shares at a price of 18.3 pence per share (as described below);

two further elements of consideration of US$1.0m each for early strategic customer wins, payable in ExchangeCo Shares and Ordinary Shares at a price of up to 18.3 pence per share, and subject to lock-up periods of 12 months;

contingent cash consideration of US$2.0m should Coastal Genomics generate revenues of at least US$4.0m for the year ended 31 March (“FY”) 2022; and

contingent cash consideration of US$4.0m should Coastal Genomics generate revenues of at least US$8.5m in FY23.

Looks like cash consideration of US$3.0m?

It doesn't explain why the Company would not pump it's own shares in order to increase the Placing price and reduce the amount of share dilution to existing shareholders.

Looking like this will close above 60 today

The UK Govt has ordered 450,000 of the tests made by Oxford Nanopore Technologies Ltd, which will be available from next week in adult care settings and laboratories.

Oxford Nanopore hasn't revealed the cost but claim it is similar or cheaper to current tests – which are around £18 privately but less to the NHS

So 450k x £18 = £8,100,000

However the Daily Mail article does summarise the other millions (wasted) on tests which will not be used.

Chuckle

https://www.dailymail.co.uk/news/article-8587591/Do-Matt-Han%coc%ks-new-coronavirus-tests-work-Scientists-urge-government-release-data.html

For you this IR approach is sufficient if not optimal others will have different views. The market will do what it wants to do. FYI Half Yearly trading update should be expected by October.

The Clarigene™ SARS-CoV-2 RUO has been selling for the last month direct from the Company and Contract Manufacturing sales and PCR reagent sales have been happening since March. Let us just agree to disagree. The Company has chosen its IR approach and the market has and will react accordingly irrespective of views held here. The science behind the test is impressive and as explained shows some clear advantages over rivals which hopefully in the coming days will be appreciated by the market

FYI the website has been updated https://www.yourgene-health.com/infectious-disease/clarigene-ce-ivd

The Company has an obligation to inform shareholders of 'material' events when they happen and not just at defined checkpoints. If a 'material' event happens at frequency so should the Investor Comms to align with the Company Code. By scheduling updates quarterly the Company can allow themselves not to inform shareholders of 'material' events such as contract announcements only to do so on the quarterly updates with predictable impacts on the sp. Comparisons have already been given on the different approach between the diagnostic companies and their IR and the market has reacted accordingly. Going further some financial services firms, travel companies are providing monthly updates. The point made by the Company was that they have upgraded their communication approach in response to shareholders concerns however if they follow just the same financial calendar timescales (Half Yearly Trading Update, Half Yearly Report, Year End Trading Update, Finals) then the change in communication approach is only slight and does not respond to concerns raised. That said, hopefully we should get other news in August.

Quarterly updates are meaningless as they will be coming alongside half yearly report.

Their RNS had a lot of figures on target volumes (450k+) which aligns with past commentary.

In terms of science the key difference is the the YGEN test uses a two viral RNA targets, nucleocapsid gene (‘N’) and envelope gene (‘E’), whereas the lamPORE test only uses one. Their test sales pitch is that it is low-cost, high-output and low-turnaround. With results in less than 2 hrs as they do not repeat the test as per PCR to guarantee an accurate result. Hence the YGEN mention on "dual viral targets and assay controls" and "100% repeatability data and an average >99.7% reproducibility".

Important differences to a clinician however perhaps not to the market.